自拍偷拍网址,亚洲不卡影院,久久天天婷婷五月俺也去

Eli Lilly 2025 H1 Report Financial statements Eli Lilly's 2025 H1 revenue surged 41% to $28.29B, driven by tirzepatide sales hitting $14.7B. Mounjaro and Zepbound shine as blockbuster drugs, boosting Lilly's global pharmaceutical ranking.
Novo Nordisk H1 2025 Financial Reports Financial statements Novo Nordisk's Semaglutide generated $16.7B in H1 2025, surpassing Keytruda as the world's top-selling drug. Strong global and China sales drive growth despite competitive challenges.
Pfizer 2025 H1 Report Financial statements Pfizer reported $28.4B in revenue for H1 2025, driven by $1.5B in ADC product sales and strong oncology growth. With $13B in BD firepower, Pfizer eyes long-term expansion across key therapeutic areas.
Small RNA Giant 2025 H1: RNAi Products Sold 8.2 Billion! Alnylam Pharmaceuticals Alnylam reports strong 2025 H1 results with $1.14B in RNAi drug sales, up 47% YoY. AMVUTTRA drives growth; stock jumps 15% as market cap surpasses $50B. Pipeline advances in Alzheimer’s, diabetes, and hypertension.
Huntsman 2025 Q2 Report Financial statements Huntsman reports a $163M loss in H1 2025 and plans a global restructuring with 10% workforce cuts. Weak demand, high costs, and plant closures drive the chemical giant's cost-saving measures.
AstraZeneca 2025 H1 Results AstraZeneca AstraZeneca reports strong H1 2025 results with $28B in revenue. Oncology leads growth, driven by Enhertu, Tagrisso, and Truqap. R&D up 16%. Strong gains in CVRM, R&I, and rare diseases.
AbbVie 2025 H1 Report AbbVie AbbVie reports strong H1 2025 results with $28.77B in revenue, driven by autoimmune leaders Skyrizi and Rinvoq. Oncology and neuroscience segments also show solid growth and strategic expansions.
GSK 2025 H1 Performance GSK GSK reports strong H1 2025 results with ￡15.5B revenue. Oncology grows 47%, HIV remains robust, and vaccines stay steady. Company targets ￡40B+ annual sales by 2031.
Sanofi 2025 h1 Performance Sanofi Sanofi reports strong 2025 H1 results with $21.8B revenue (+9.9%), driven by Dupixent sales hitting $8B and RSV antibody Beyfortus growing 79%. Rare disease drugs and BD deals also highlight growth momentum.
Axalta 2025 H1 Performance Axalta Axalta reported H1 2025 revenue of $2.567B, down 2.95% YoY, with China sales up 9% to ￥2.1B. Strong Q2 profits driven by cost control and growth in mobility coatings despite lower volumes.

< Pre 1 2 345 6 7 8...15 Next >

Articles Archives

Hot Articles

All Categories

Agri & Industry Cosmetic Laboratory Pharmaceutical Food

永久免费毛片_亚洲成人看片_亚洲春色另类_亚洲综合免费视频_最新高清无码专区_午夜影院a